○ CBD as a Treatment for Acne?

○ CBD exerts sebostatic and antiinflammatory effects on human sebocytes

○ The endocannabinoid system of the skin in health and disease

○ Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes

○ via cannabinoid receptor-2-mediated signaling

○ Endocannabinoid signaling and epidermal differentiation

○ Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions

○ Searching for a neurobiological basis for self-medication theory in ADHD comorbid with substance use disorders: an in vivo study of dopamine transporters using (99m)Tc-TRODAT-1 SPECT.

○ Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats.

○ Self-medication with cannabidiol oil in a patient with primary lateral sclerosis

○ Neurological aspects of medical use of CBD

○ Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

○ The therapeutic potential of the endocannabinoid system for Alzheimer's disease.

○ Endocannabinoid signalling in Alzheimer's disease.

○ Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells.

○ The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease.

○ Cannabinoids for the treatment of dementia.

○ Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression.

○ Cannabidiol: a promising drug for neurodegenerative disorders?

○ The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses.

○ The role of phytochemicals in the treatment and prevention of dementia.

○ Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARγ involvement.

○ Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic.

○ Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

○ Natural Phytochemicals in the Treatment and Prevention of Dementia.

○ In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease.

○ Neurological Aspects of Medical Use of Cannabidiol.○

○ Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.

○ Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

○ Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.

○ Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation.

○ Effects of cannabidiol (CBD) on regional cerebral blood flow

○ The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors.

○ The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.

○ Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.

○ A Systematic Review of Plant-Derived Natural Compounds for Anxiety Disorders.

○ The Endocannabinoid System and Anxiety.

○ Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

○ Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats.

○ Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report.

○ Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults.

○ Endocannabinoid Signaling in Autism

○ Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders.

○ A Novel Approach to the Symptomatic Treatment of Autism

○ Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders.

○ Targeting the endocannabinoid system in the treatment of fragile X syndrome.

○ Deficient adolescent social behavior following early-life inflammation is ameliorated by augmentation of anandamide signaling.

○ Medicinal marijuana stops seizures, brings hope to a little girl

○ Canabinoids and the brain

○ Cannabis, cannabidiol, and epilepsy -- from receptors to clinical response

○ Chronic administration of cannabidiol to healthy volunteers and epileptic patients.

○ Endocannabinoid system protects against cryptogenic seizures.

○ Seizing an opportunity for the endocannabinoid system.

○ Cannabidiol: promise and pitfalls.

○ Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures.

○ Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.

○ Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.

○ The endocannabinoid system: an emerging key player in inflammation.

○ Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice.

○ Cannabinoids, endocannabinoids, and related analogs in inflammation.

○ Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor.

○ Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.

○ Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis.

○ Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation.

○ Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement.

○ Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption.

○ Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation.

○ Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death.

○ Cannabinoids in clinical practice.

○ Cannabinoids, inflammation, and fibrosis.

○ Endocannabinoid 2-arachidonoylglycerol protects inflammatory insults from sulfur dioxide inhalation via cannabinoid receptors in the brain.

○ Protective effect of cannabidiol on hydrogen peroxide‑induced apoptosis, inflammation and oxidative stress in nucleus pulposus cells.

○ Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis.

○ Cannabinoids for neuropathic pain.

○ Neuropathic orofacial pain: cannabinoids as a therapeutic avenue.

○ Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation.

○ Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.

○ Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.

○ Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.

○ Cannabinoids in the management of difficult to treat pain.

○ Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats.

○ Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats.

○ Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults.

○ CBD modulates sleep in rats 

○ Endocannabinoid modulation of cortical up-states and NREM sleep.

○ Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat.

○ Endocannabinoid Signaling Regulates Sleep Stability.

○ Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder

○ Endogenous cannabinoid signaling is essential for stress adaptation.

○ Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders.

○ Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output.

○ Neuromodulators, stress and plasticity: a role for endocannabinoid signaling.

○ Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress.

○ Endocannabinoids and stress.

○ Stress regulates endocannabinoid-CB1 receptor signaling.

○ Chronic stress impairs α1-adrenoceptor-induced endocannabinoid-dependent synaptic plasticity in the dorsal raphe nucleus.

○ Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological significance.

○ Cannabinoid receptor activation prevents the effects of chronic mild stress on emotional learning and LTP in a rat model of depression.

○ Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory.

○ The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.

○ Low-frequency stimulation evokes serotonin release in the nucleus accumbens and induces long-term depression via production of endocannabinoid.

○ Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice.

○ Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance.

○ Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke.